Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to $656.2 million.

  • Vanda Pharmaceuticals' Liabilities and Shareholders Equity fell 6.82% to $601.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 3.22%. This contributed to the annual value of $656.2 million for FY2024, which is 1.20% up from last year.
  • According to the latest figures from FY2024, Vanda Pharmaceuticals' Liabilities and Shareholders Equity is $656.2 million, which was up 1.20% from $648.4 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $656.2 million during FY2024, and its lowest value of $533.5 million during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $648.4 million (2023), whereas its average is $646.3 million.
  • Data for Vanda Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY rose of 11.31% (in 2021) over the last 5 years.
  • Vanda Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $533.5 million in 2020, then rose by 11.31% to $593.8 million in 2021, then increased by 6.81% to $634.2 million in 2022, then rose by 2.24% to $648.4 million in 2023, then increased by 1.20% to $656.2 million in 2024.